Applied Clinical Trials-06-01-2019

FDA draft guidance for modernizing the approach to clinical trial design for oncology drugs and biologics look to make clinical trials more efficient while maintaining patient safety.

C.K. Wang, MD, senior medical director at COTA Inc., discusses the impact of RWD and RWE in clinical oncology.

A look at three contemporary trends that though integrated cautiously at first, may open up a reimagined world of clinical research.

A look at the latest oncology stats and information most applicable to the clinical trials industry practice.

Researchers and sponsors are looking to use RWE information to help in trial design, product use, developing new therapies, and gaining market approval.

A compilation of recently released news briefs that pertain to the clinical trials industry.

Click the title above to open the Applied Clinical Trials June 2019 issue in an interactive PDF format.

The World Health Organization tries to find a balance with its Road Map for Access on how to best approach research and pricing in Europe.

Exploring the Institute for Neurodegenerative Disorders’ non-traditional approach to engaging community physicians.

Undertaking an assessment of the POS can be coupled with the product profile and safety assessments of compounds prior to launching a clinical trial.

Record numbers point to new R&D operating environment, driven by a changing community of sponsors.

Using a risk-based model to navigate the inherent changes and fluctuations in master protocol studies-and help maintain data integrity throughout.

Examining the fundamental changes required to successfully integrate clinical research into mainstream healthcare.